Preventing HIV antiretroviral resistance through better monitoring of treatment adherence

Journal of Infectious Diseases

Volumn 197, Issue SUPPL. 3, 2008, Pages

  Bangsberg, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DARUNAVIR; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; LAMIVUDINE; MARAVIROC; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL RESISTANCE; BEHAVIOR THERAPY; CHRONIC DISEASE; CLINICAL PRACTICE; COMPUTER SYSTEM; COST EFFECTIVENESS ANALYSIS; DATA ANALYSIS SOFTWARE; DATA STORAGE DEVICE; DRUG INFORMATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INFORMATION RETRIEVAL; INTERNET; ONLINE MONITORING; PATIENT ASSESSMENT; PATIENT ATTITUDE; PATIENT CARE PLANNING; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT MONITORING; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SELF REPORT; TREATMENT RESPONSE; VIRUS LOAD;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PATIENT COMPLIANCE;

EID: 44149085204     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/533415     Document Type: Review

References (78)

1. Bangsberg DR, Moss A. When should we delay highly active antiretroviral therapy? [editorial]. J Gen Intern Med 1999; 14:446-8.
2. Dalessandro M, Conti CM, Gambi F, et al. Antidepressant therapy can improve adherence to antiretroviral regimens among HIV-infected and depressed patients. J Clin Psychopharmacol 2007; 27:58-61.
3. Sullivan LE, Barry D, Moore BA, et al. A trial of integrated buprenorphine/naloxone and HIV clinical care. Clin Infect Dis 2006; 43(Suppl 4):S184-90.
4. Lucas GM, Gebo KA, Chaisson RE, Moore RD. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS 2002; 16:767-74.
5. Arnsten JH, Demas PA, Grant RW, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med 2002; 17:377-81.
6. Beach MC, Keruly J, Moore RD. Is the quality of the patient-provider relationship associated with better adherence and health outcomes for patients with HIV? J Gen Intern Med 2006; 21:661-5.
7. Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 28:47-58.
8. Remien RH, Stirratt MJ, Dolezal C, et al. Couple-focused support to improve HIV medication adherence: a randomized controlled trial. AIDS 2005; 19:807-14.
9. Mannheimer S, Friedland G, Matts J, Child C, Chesney M. The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials. Clin Infect Dis 2002; 34:1115-21.
10. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. J Acquir Immune Defic Syndr 2006; 41:315-22.
11. Parruti G, Manzoli L, Toro PM, et al. Long-term adherence to first-line highly active antiretroviral therapy in a hospital-based cohort: predictors and impact on virologic response and relapse. AIDS Patient Care STDS 2006; 20:48-56.
12. Chaudhry SI, Phillips CO, Stewart SS, et al. Telemonitoring for patients with chronic heart failure: a systematic review. J Card Fail 2007; 13: 56-62.
13. Goetzel RZ, Ozminkowski RJ, Villagra VG, Duffy J. Return on investment in disease management: a review. Health Care Financ Rev 2005; 26:1-19.
14. Simoni JM, Pearson CR, Pantalone DW, Marks G, Crepaz N. Efficacy of interventions in improving highly active antiretroviral therapy adherence and HIV-1 RNA viral load: a meta-analytic review of randomized controlled trials. J Acquir Immune Defic Syndr 2006; 43(Suppl 1):S23-35.
15. Amico KR, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. J Acquir Immune Defic Syndr 2006; 41:285-97.
16. Wagner GJ, Kanouse DE, Golinelli D, et al. Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578). AIDS 2006; 20:1295-302.
17. Weber R, Christen L, Christen S, et al. Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial. Antivir Ther 2004; 9:85-95.
18. Golin CE, Earp J, Tien HC, Stewart P, Porter C, Howie L. A 2-arm, randomized, controlled trial of a motivational interviewing-based intervention to improve adherence to antiretroviral therapy (ART) among patients failing or initiating ART. J Acquir Immune Defic Syndr 2006; 42:42-51.
19. Mannheimer SB, Morse E, Matts JP, et al. Sustained benefit from a long-term antiretroviral adherence intervention: results of a large randomized clinical trial. J Acquir Immune Defic Syndr 2006; 43(Suppl 1):S41-7.
20. Rathbun RC, Farmer KC, Stephens JR, Lockhart SM. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study. Clin Ther 2005; 27:199-209.
21. Collier AC, Ribaudo H, Mukherjee AL, Feinberg J, Fischl MA, Chesney M. A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy. J Infect Dis 2005; 192:1398-406.
22. Andrade AS, McGruder HF, Wu AW, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-infected subjects with memory impairment. Clin Infect Dis 2005; 41:875-82.
23. Williams AB, Fennie KP, Bova CA, Burgess JD, Danvers KA, Dieckhaus KD. Home visits to improve adherence to highly active antiretroviral therapy: a randomized controlled trial. J Acquir Immune Defic Syndr 2006; 42:314-21.
24. Mitty JA, McKenzie M, Stenzel M, Flanigan T, Carpenter CC. Modified directly observed therapy for treatment of human immunodeficiency virus [letter]. JAMA 1999; 282:1334.
25. Lucas GM, Mullen BA, Weidle PJ, Hader S, McCaul ME, Moore RD. Directly administered antiretroviral therapy in methadone clinics is associated with improved HIV treatment outcomes, compared with outcomes among concurrent comparison groups. Clin Infect Dis 2006; 42:1628-35.
26. Altice FL, Maru DS, Bruce RD, Springer SA, Friedland GH. Superiority of directly administered antiretroviral therapy over self-administered therapy among HIV-infected drug users: a prospective, randomized, controlled trial. Clin Infect Dis 2007; 45:770-8.
27. Kirkland LR, Fischl MA, Tashima KT, et al. Response to lamivudinezidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment. Clin Infect Dis 2002; 34:511-8.
28. Bangsberg D, Hecht F, Clague H, et al. Provider assessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:435-42.
29. Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS 2002; 16:1835-7.
30. Miller LG, Liu H, Hays RD, et al. How well do clinicians estimate patients' adherence to combination antiretroviral therapy? J Gen Intern Med 2002; 17:1-11.
31. Lucas GM, FlexnerCW, Moore RD. Directly administered antiretroviral therapy in the treatment of HIV infection: benefit or burden? AIDS Patient Care STDS 2002; 16:527-35.
32. Wohl AR, Garland WH, Valencia R, et al. A randomized trial of directly administered antiretroviral therapy and adherence case management intervention. Clin Infect Dis 2006; 42:1619-27.
33. Goldie SJ, Paltiel AD, Weinstein MC, et al. Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection. Am J Med 2003; 115:632-41.
34. Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 2001; 28:445-9.
35. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S140-4.
36. Roberts KJ, Volberding P. Adherence communication: a qualitative analysis of physician-patient dialogue. AIDS 1999; 13:1771-8.
37. Chesney MA, Ickovics JR, Chambers DB, et al. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instruments. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-66.
38. Amico KR, Fisher WA, Cornman DH, et al. Visual analog scale of ART adherence: association with 3-day self-report and adherence barriers. J Acquir Immune Defic Syndr 2006; 42:455-9.
39. Simoni JM, Kurth AE, Pearson CR, Pantalone DW, Merrill JO, Frick PA. Self-report measures of antiretroviral therapy adherence: a review with recommendations for HIV research and clinical management. AIDS Behav 2006; 10:227-45.
40. Giordano T, Guzman D, Clark R, Charlebois E, Bangsberg D. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials 2004; 5:74-9.
41. Bangsberg DR, Bronstone A, Chesney MA, Hecht FM. Computer-assisted self-interviewing (CASI) to improve provider assessment of adherence in routine clinical practice. J Acquir Immune Defic Syndr 2002; 31(Suppl 3):S107-11.
42. Gifford A. Optimizing clinical and research assessment of ART adherence. In: Program and abstracts of the 2nd International Conference on HIV Treatment Adherence (Jersey City). Chicago: International Association of Physicians in AIDS Care, 2007.
43. Bangsberg DR, Bronstone A, Hofmann R. A computer-based assessment detects regimen misunderstandings and nonadherence for patients on HIV antiretroviral therapy. AIDS Care 2002; 14:3-15.
44. Des Jarlais DC, Paone D, Milliken J, et al. Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasirandomised trial. Lancet 1999; 353:1657-61.
45. Parienti J, Massari V, Descamps D, et al. Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine or efavirenz-based antiretroviral therapy. Clin Infect Dis 2004; 38:1311-6.
46. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol 1997; 50:105-16.
47. Steiner JF, Koepsell TD, Fihn SD, Inui TS. A general method of compliance assessment using centralized pharmacy records: description and validation. Med Care 1988; 26:814-23.
48. Low-Beer S, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Adherence to triple therapy and viral load response. J Acquir Immune Defic Syndr 2000; 23:360-1.
49. Gross R, Zhang Y, Grossberg R. Medication refill logistics and refill adherence in HIV. Pharmacoepidemiol Drug Saf 2005; 14:789-93.
50. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191:339-47.
51. Hogg RS, Heath K, Bangsberg D, et al. Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up. AIDS 2002; 16:1051-8.
52. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor -based HIV therapy and virologic outcomes. Ann Intern Med 2007; 146:564-73.
53. Gross R, Yip B, Lo Re V III, et al. A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. J Infect Dis 2006; 194:1108-14.
54. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS 2000; 14:357-66.
55. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS 2001; 15:1181-3.
56. Bangsberg DR, Charlebois ED, Grant RM, et al. High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 2003; 17:1925-32.
57. Kalichman SC, Amaral CM, Stearns H, et al. Adherence to antiretroviral therapy assessed by unannounced pill counts conducted by telephone. J Gen Intern Med 2007; 22:1003-6.
58. Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. Clin Infect Dis 2001; 33: 1417-23.
59. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 2000; 133:21-30.
60. Arnet I, Haefeli WE. Overconsumption detected by electronic drug monitoring requires subtle interpretation. Clin Pharmacol Ther 2000; 67:44-7.
61. Bangsberg D, Hecht F, Charlebois E, Chesney M, Moss A. Comparing objectives measures of adherence to HIV antiretroviral therapy: electronic medication monitors and unannounced pill counts. AIDS Behav 2001; 5:275-81.
62. Golin CE, Liu H, Hays RD, et al. A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med 2002; 17:756-65.
63. Petersen M, Wang Y, van der Laan M, David Guzman D, Elise Riley E, Bangsberg D. Pill box organizers are associated with improved adherence to HIV antiretroviral therapy and viral suppression: a marginal structural model analysis. Clin Infect Dis 2007; 45:908-15.
64. Ruskin P, Van der Wende J, Clark C, et al. Feasibility of using the Med-eMonitor system in the treatment of schizophrenia: a pilot study. Drug Inf J 2003; 37:283-91.
65. Maggiolo F, Ravasio L, Ripamonti D, et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 2005; 40: 158-63.
66. Bangsberg DR. Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 2006; 43:939-41.
67. Gross R, Yip B, Wood E, et al. Boosted PI are more forgiving of suboptimal adherence than non-boosted PI or NNRTI [abstract 533]. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (Denver). Alexandria, VA: Foundation for Retrovirology and Human Health, 2006.
68. Bangsberg D, Ragland K, Hahn JA, et al. No difference in adherence or viral suppression to ritonavir boosted protease inhibitor (r-PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) regimens. In: Program and abstracts of the 2nd International Conference on HIV Treatment Adherence (Jersey City). Chicago: International Association of Physicians in AIDS Care, 2007.
69. Bangsberg DR, Kroetz DL, Deeks SG. Adherence-resistance relationships to combination HIV antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:65-72.
70. Bangsberg DR, Acosta EP, Gupta R, et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS 2006; 20:223-31.
71. Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 2004; 18:1965-6.
72. Oyugi JH, Byakika-Tusiime J, Ragland K, et al. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 2007; 21:965-71.
73. McNabb J, Ross JW, Abriola K, Turley C, Nightingale CH, Nicolau DP. Adherence to highly active antiretroviral therapy predicts virologic outcome at an inner-city human immunodeficiency virus clinic. Clin Infect Dis 2001; 33:700-5.
74. Gardner EM, Burman WJ, Maravi ME, Davidson AJ. Selective drug taking during combination antiretroviral therapy in an unselected clinic population. J Acquir Immune Defic Syndr 2005; 40:294-300.
75. Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single-drug therapy for maintenance of HIV-1 viral suppression: 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005; 40:280-7.
76. McKinnon JE, Arribas JR, Pulido F, Delgado R, Mellors JW. The level of persistent HIV viremia does not increase after successful simplification of maintenance therapy to lopinavir/ritonavir alone. AIDS 2006; 20:2331-5.
77. Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA 2006; 296:806-14.
78. Relling MV, Hoffman JM. Should pharmacogenomic studies be required for new drug approval? Clin Pharmacol Ther 2007; 81:425-8.